Literature DB >> 19258276

Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Ken B Waites1, D M Crabb, Lynn B Duffy.   

Abstract

MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19258276      PMCID： PMC2681567          DOI： 10.1128/AAC.00090-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.

Authors:  Satowa Suzuki; Tsutomu Yamazaki; Mitsuo Narita; Norio Okazaki; Isao Suzuki; Tomoaki Andoh; Mayumi Matsuoka; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 3.  Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.

Authors:  John R Lonks; Donald A Goldmann
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

4.  In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.

Authors:  C M Bebear; H Renaudin; A Charron; D Gruson; M Lefrancois; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Fluoroquinolone resistance in Ureaplasma parvum in the United States.

Authors:  Lynn Duffy; John Glass; Geraldine Hall; Robin Avery; Raymond Rackley; Scott Peterson; Ken Waites
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

6.  Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.

Authors:  Mayumi Matsuoka; Mitsuo Narita; Norio Okazaki; Hitomi Ohya; Tsutomu Yamazaki; Kazunobu Ouchi; Isao Suzuki; Tomoaki Andoh; Tsuyoshi Kenri; Yuko Sasaki; Atsuko Horino; Miharu Shintani; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  Mycoplasmas and ureaplasmas as neonatal pathogens.

Authors:  Ken B Waites; Brenda Katz; Robert L Schelonka
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years.

Authors:  S Pereyre; A Charron; H Renaudin; C Bébéar; C M Bébéar
Journal:  J Clin Microbiol       Date:  2007-09-19       Impact factor: 5.948
View more
  30 in total

1.  Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Authors:  Brian D Jamieson; Sabrina Ciric; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  CEM-101 activity against Gram-positive organisms.

Authors:  Leah N Woosley; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors:  J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide.

Authors:  Ronald N Jones; James E Ross; Paul R Rhomberg
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

5.  In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Authors:  Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

6.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

Review 7.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

8.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Authors:  Jørgen Skov Jensen; Prabhavathi Fernandes; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

9.  Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; J Gordon Still; Kay Clark; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

Review 10.  The Human Ureaplasma Species as Causative Agents of Chorioamnionitis.

Authors:  Emma L Sweeney; Samantha J Dando; Suhas G Kallapur; Christine L Knox
Journal:  Clin Microbiol Rev       Date:  2016-12-14       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.